New Drug Shows Promise in Reducing Diabetes Complications & Boosting Healing

An experimental compound is showing promise in reducing the damaging effects of diabetes, potentially offering a new approach to treatment. Research conducted at NYU Langone Health has identified a drug candidate that limits cell death, reduces inflammation and lessens organ damage associated with the disease, as demonstrated in mouse studies.

Blocking a Key Protein Interaction Boosts Healing

The findings, recently published in Cell Chemical Biology, center on preventing the interaction between two proteins: RAGE and DIAPH1. Keeping these proteins from connecting eases swelling in diabetic tissues and promotes more efficient repair, according to the research.

The compound, known as RAGE406R, is a small molecule designed to target RAGE. Tests in both human cells and mouse models showed significant reductions in both immediate and long-term complications associated with Type 1 and Type 2 diabetes.

Did You Know? Researchers screened a library of over 58,000 molecules to identify those that interfered with the RAGE-DIAPH1 pathway.

“There are currently no treatments that address the root causes of diabetic complications, and our work shows that RAGE406R can — not by lowering the high blood sugar, but instead by blocking the intracellular action of RAGE,” explained co-senior study author Ann Marie Schmidt, MD, the Dr. Iven Young Professor of Endocrinology at the NYU Grossman School of Medicine.

Dr. Schmidt added that if confirmed through human trials, the compound could address gaps in current treatment options, particularly as most existing drugs primarily target Type 2 diabetes.

How RAGE and DIAPH1 Contribute to Damage

RAGE is a receptor protein that responds to advanced glycation end products (AGEs). AGEs form when proteins or fats bind to sugars, a process that happens more often in people with diabetes. These molecules accumulate in the bloodstream in individuals with diabetes and obesity, and also increase naturally with age.

RAGE406R works by competing for the binding site on RAGE that DIAPH1 normally occupies. DIAPH1 plays a role in forming actin filaments, which are essential components of a cell’s internal structure. The research team found that when DIAPH1 connects to RAGE, it intensifies diabetic complications by increasing the formation of actin structures.

Expert Insight: This research represents a shift in focus for diabetes treatment, moving away from solely managing blood sugar levels and toward addressing the underlying mechanisms that drive complications.

The team developed RAGE406R after identifying concerns with an earlier compound, RAGE229, which showed potential safety risks related to DNA alteration. RAGE406R was engineered to remove the problematic structural element.

Testing RAGE406R on obese mice with Type 2 diabetes and delayed wound healing demonstrated its effectiveness. Applying the compound directly to the skin accelerated wound closure in both male and female mice.

Reducing Misplaced Inflammation to Support Repair

The benefits of RAGE406R also extend to its impact on the immune system. The compound lowered levels of CCL2, a signaling molecule that promotes inflammation. By reducing CCL2 activity, RAGE406R calmed inflammation in macrophages, a type of immune cell, and supported tissue remodeling—a crucial part of the healing process.

“Our findings point to a promising new pathway for treating diabetes in the future,” said co-senior study author Alexander Shekhtman, PhD, a professor in the Department of Chemistry at the State University of New York (SUNY) at Albany. “The current study results serve as a springboard for the development of therapies for both types of diabetes, and for designing markers that can measure how well the new treatment works in live animals.”

Frequently Asked Questions

What is RAGE406R?

RAGE406R is an experimental drug candidate, a small molecule designed to prevent the interaction between the RAGE protein and DIAPH1.

What role do RAGE and DIAPH1 play in diabetes?

When RAGE and DIAPH1 interact, they contribute to heart and kidney injury linked to diabetes and slow the healing of wounds.

What type of studies have been conducted on RAGE406R?

Studies have been conducted in both human cells and mouse models, showing reductions in complications associated with Type 1 and Type 2 diabetes.

Could a treatment targeting the RAGE-DIAPH1 interaction represent a significant advancement in managing the long-term effects of diabetes?